BioNexus Gene Lab Corp secured an exclusive license for its CogniAI platform to support Malaysia's RM1 billion public healthcare digitization program, targeting 150 hospitals and 2,000 clinics through
BioNexus Gene Lab Corp filed a Form 3 statement revealing Fidelion Diagnostics Pte. Ltd holds over 5% of common shares. The filing identifies Fidelion as a greater-than-5% holder with 392,329 shares a
BioNexus Gene Lab Corp filed an initial Form 3 for CFO Chong Set Fui on June 17, 2025, disclosing beneficial ownership details to the U.S. Securities and Exchange Commission.
BioNexus Gene Lab Corp announced progress commercializing its VitaGuard™ molecular residual disease platform in Southeast Asia after technical planning visits to Chinese facilities. The company aims t
BioNexus Gene Lab Corp plans to commercialize its VitaGuard MRD liquid-biopsy platform in Southeast Asia by 2026, with test costs projected under $300. The rollout follows successful paid use in China
Financial analysis data for BioNexus Gene Lab Corp (NASDAQ: BGLC) details its Enterprise Value to EBITDA forward ratio on a TradingView page.
BioNexus Gene Lab advocates deepening Malaysia-China biotech collaboration into co-development and clinical validation, positioning Malaysia as an ASEAN execution hub. The strategy utilizes platforms
BioNexus Gene Lab urged Malaysia-China biotech co-development at the 2026 China-Malaysia Economic Cooperation Outlook Forum, proposing a precision healthcare corridor. The firm noted that a Nasdaq lis
BioNexus Gene Lab advocated for deeper Malaysia-China biotech cooperation at the 2026 Economic Cooperation Outlook Forum. CEO Sam Tan proposed positioning Malaysia as an ASEAN hub to accelerate the co
BioNexus Gene Lab Corp advocated for deeper Malaysia-China biotech collaboration at the 2026 Economic Cooperation Outlook Forum. CEO Sam Tan proposed a precision healthcare corridor to facilitate cros
BioNexus Gene Lab Corp reported Q1 2026 revenue of $22.84K, down 98.9% year-over-year, while reducing net loss per share to $0.23. The company plans to pivot toward CDMO services and VitaGuard MRD com
BioNexus Gene Lab reported fiscal-year revenue of $7.42 million, down 21.9% due to lower Chemrex volume and foreign exchange. Despite an operating loss increase, gross margins improved to 14.7% as the
BioNexus Gene Lab Corp shares fell 3.08% to $2.18 amid poor technical and fundamental ratings, while operating in chemical raw materials and genomic screening.
BioNexus Gene Lab Corp. appointed Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics to lead global commercialization of the VitaGuard™ MRD precision oncology platform. The appointment aims to strengt
BioNexus Gene Lab Corp. finalized governance restructuring of subsidiary Chemrex Corporation, appointing Matthew Barsing as Chairman to streamline oversight. This move supports disciplined capital all
ChemBrief